Saccular Aneurysm No Bar to Thrombolysis in Ischemic Stroke Saccular Aneurysm No Bar to Thrombolysis in Ischemic Stroke
Thrombolysis appears to be relatively safe in stroke patients with saccular unruptured intracranial aneurysms but may increase risk for rupture in those with large fusiform aneurysms.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 8, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO ® (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events
RARITAN, NJ, September 27, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data from the Phase 3 UNIVERSE study showing treatment with XARELTO® (rivaroxaban) in an oral suspension formulation, compared to treatment with aspirin, was associated with numerically fewer blood clots and clinical events strongly associated with blood clots in pediatric patients (aged 2-8 years) who have undergone the Fontan procedure. [1] These findings, which were published this month in the Journal of the American Heart Association and included in a recent New Drug Application submitted to the U.S. F...
Source: Johnson and Johnson - September 27, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Stroke: The signs in the eyes that could foreshadow an acute incident
STROKE is one of the leading causes of death and disability worldwide, but not all incidents are characterised by overt symptoms. A transient ischaemic attack - or mini stroke - will often be brushed off as a minor mishap. These transient symptoms, however, often signal a subsequent fatal or disabling stroke. Four signs in the eyes could signal an undetected mini-stroke, according to Doctor Clare O'Donnell. (Source: Daily Express - Health)
Source: Daily Express - Health - September 18, 2021 Category: Consumer Health News Source Type: news
Ticagrelor of Net Clinical Benefit aAfter Stroke, TIA: THALES Ticagrelor of Net Clinical Benefit aAfter Stroke, TIA: THALES
A new analysis of data from the THALES trial separates out the reduction in ischemic events from the increase in bleeding events and shows the benefit outweighs the risk in a ratio of four-to-one.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - September 18, 2021 Category: Internal Medicine Tags: Neurology & Neurosurgery News Source Type: news
Ticagrelor of Net Clinical Benefit After Stroke, TIA: THALES Ticagrelor of Net Clinical Benefit After Stroke, TIA: THALES
A new analysis of data from the THALES trial separates out the reduction in ischemic events from the increase in bleeding events and shows the benefit outweighs the risk in a ratio of four-to-one.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 17, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Aspirin and Heparin Increase Bleeding Risk During EVT Aspirin and Heparin Increase Bleeding Risk During EVT
New data from MR CLEAN-MED show that aspirin and heparin, alone or in combination, double the risk for symptomatic intracranial hemorrhage when given during endovascular therapy (EVT) for ischemic stroke.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 15, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
What's the Right TIMING for NOAC After Ischemic Stroke? What's the Right TIMING for NOAC After Ischemic Stroke?
Early treatment with novel oral anticoagulants is noninferior to delayed treatment among patients with ischemic stroke and atrial fibrillation, according to data from a registry-based randomized trial.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 14, 2021 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news
ERLEADA ® (apalutamide) Oral Presentations Demonstrate Importance of Prostate Specific Antigen (PSA) as Key Efficacy Indicator and Show Strong Patient Adherence Rates
September 11, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data demonstrating robust prostate-specific antigen (PSA) response and strong adherence rates in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with ERLEADA® (apalutamide) in the real-world clinical setting. The strong PSA response was also seen in a separate post-hoc analysis that showed a correlation between rapid and deep PSA response and prolonged survival in both metastatic castration-sensitive prostate cancer (mCSPC) and nmCRPC. The post-hoc analysis also suppor...
Source: Johnson and Johnson - September 12, 2021 Category: Pharmaceuticals Source Type: news
Mobile Stroke Units Linked to Reduced Stroke Disability Mobile Stroke Units Linked to Reduced Stroke Disability
In an observational study of patients with acute ischemic stroke, treatment in a mobile stroke unit was associated with better functional outcomes than treatment by emergency medical services.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 9, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
' No Reason to Drop tPA' in Stroke Thrombectomy: SWIFT DIRECT'No Reason to Drop tPA' in Stroke Thrombectomy: SWIFT DIRECT
A new study has failed to show noninferiority of direct thrombectomy compared to bridging therapy with thrombolysis before thrombectomy for patients with large-vessel occlusion ischemic stroke.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 2, 2021 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news
Striving to Deliver Better Outcomes: Janssen to Showcase Commitment to Advancing Science for Genitourinary Cancers at AUA 2021
August 31, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple company-sponsored presentations in prostate and bladder cancers will be highlighted at the virtual 2021 American Urological Association Annual Meeting (AUA 2021), September 10-13. “Janssen maintains a strong commitment to advancing innovation and new therapeutic options for patients with genitourinary malignancies. As the treatment of genitourinary cancers becomes more complex, we continue to work with urologists and their teams to improve outcomes for patients across the continuum of disease,” sai...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
FDA OKs First Vagus Nerve Stimulation System for Stroke Rehab FDA OKs First Vagus Nerve Stimulation System for Stroke Rehab
The US Food and Drug Administration has approved a first-of-its kind vagus nerve stimulation system to treat moderate-to-severe upper extremity motor deficits associated with chronic ischemic stroke.FDA Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 27, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news
FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Regional Stroke Triage by EMS Ups Endovascular Therapy Rate
FRIDAY, Aug. 20, 2021 -- Implementation of a regional prehospital transport policy for comprehensive stroke center triage may result in a significant increase in endovascular therapy (EVT) rates among patients with acute ischemic stroke and large... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 20, 2021 Category: Pharmaceuticals Source Type: news
